There are two types of treatments.

The Intragastric Balloon was developed for temporary induction of weight loss in obese or overweight patients. It can be used as a preliminary treatment for those suffering from obesity whose condition does not justify surgical intervention. ⁵,⁶

Composed of a silicone capsule, a one-way valve system, and a radiopaque surface, both resistant to contact with gastric juice. The valve system connects to the conduction and filling tube, used for conducting and filling the balloon. ⁵,⁶

Placed in the stomach and filled with saline solution, causing the balloon to expand into a spherical shape. The filled balloon is designed to act as a space filler and move freely within the stomach.⁶

6 months

The Intragastric Balloon is indicated for temporary use in weight loss therapy for overweight patients over 18 years of age with a Body Mass Index (BMI) of 27 kg/m² or higher.
The Intragastric Balloon should remain in the patient for a maximum of 6 months and should be removed within this period or even earlier, as directed by a physician.⁵

12 months

Indicated for patients with a Body Mass Index (BMI) above 40 kg/m², as well as for those with a BMI above 35 kg/m² who have comorbidities aggravated by obesity. The treatment provides a significant improvement in the quality of life of patients, reducing the risk of associated diseases such as type 2 diabetes, sleep apnea, hypertension, dyslipidemia, coronary heart disease, osteoarthritis, among others.

The Intragastric Balloon can also be used as an adjunct in weight loss treatment, especially in the preoperative preparation of patients with super obesity (BMI above 50 kg/m²), in cases of associated pathologies aggravated and/or triggered by morbid obesity.⁶

The Intragastric Balloon should be used in conjunction with a supervised, long-term diet and a behavior modification program to increase the likelihood of maintaining long-term weight loss.⁵

This procedure must be performed in a hospital with the infrastructure to handle any complications. ⁵,⁶

How it works

The patient must fast for 12 hours.⁵ ,⁶
The Intragastric Balloon is supplied empty and packaged within a silicone sheath, both attached to the conduction and filling tube, allowing for endoscopic insertion. It has an auxiliary filling tube with a three-way valve, clamp, and perforator for saline solution bags in a closed system model.⁵

The amount should be adjusted according to the patient's biotype, for a filling volume that can vary between 400 and 700 mL of
saline solution and methylene blue, for a period of 6 or 12 months in the stomach. ⁵,⁶

Methylene blue saline solution is indicated so that, in case of leakage or rupture of the balloon, this blue-colored liquid is expelled in the urine, identifying the need for its removal. ⁷

It is recommended that the patient be monitored throughout their stay by a multidisciplinary team consisting of psychologists, nutritionists, endocrinologists, endoscopists, and surgeons trained and qualified in the treatment of obesity. ⁵,⁶

Made of silicone.

During the endoscopy procedure, the Corporea Intragastric Balloon is filled with saline solution and methylene blue, from 400mL to 700mL, and remains in place for up to 6 or 12 months, depending on the indicated treatment. ⁵,⁶

1. Crossan K, Sheer AJ. Intragastric Balloon. 2023 Jan 30. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. Available at: https://pubmed.ncbi.nlm.nih.gov/3520171 2/. Accessed on: 09 Jan. 2025.

2. Stavrou G, Shrewsbury A, Kotzampassi K. Six intragastric balloons: Which to choose? World J Gastrointest Endosc. 2021 Aug 16;13(8):238-59.

3.Shah RH, Vedantam S, Kumar S, Amin S, Pearlman M, Bhalla S. Intragastric Balloon Significantly Improves Metabolic Parameters at 6 Months: a Meta-Analysis. Obes Surg. 2023 Mar;33(3):725-32.

4.Pietrabissa G, Bertuzzi V, Simpson S, Guerrini Usubini A, Cattivelli R, Bertoli S, et al. Psychological Aspects of Treatment with Intragastric Balloon for Management of Obesity: A Systematic Review of the Literature. Obes Facts. 2022;15(1):1-18.

5. Instructions for Use: Corporea Balloon 6 months.

6. Instructions for Use of the Corporea 12-Month Intragastric Balloon.

7. Carvalho, Mª Raquel et al. Intragastric Balloon in the Treatment of Morbid Obesity. Acta Médica Portuguesa, [Sl], v. 24, p. 489-498, 2011.

Consult your doctor to find out if the intragastric balloon is the right option for you.

Product features:

☉ During the endoscopy procedure, the Corporea Intragastric Balloon is filled with saline solution and methylene blue. The balloon volume will be between 400mL and 700mL. ^5,6

☉ It is made of medical-grade silicone, resistant to contact with gastric juices. ^5.6

☉ Supplied empty, packaged in a containment membrane and attached to the conduit and filling tube, allowing its introduction via endoscopy. ^5,6

Contraindications:

The use of the Intragastric Balloon is contraindicated in the following cases: ⁵,⁶

☉ Pregnant women or women during breastfeeding;
☉ People unable or unwilling to comply with dietary restrictions or medical supervision and their respective guidelines during use;
☉ Patients with psychiatric disorders;
☉ Patients under 18 years of age;
☉ Individuals with severe kidney and/or liver disease;
☉ Patients who have undergone previous gastric or intestinal surgery;
☉ Patients with inflammatory bowel diseases requiring prior treatment;
☉ Patients with inflammatory bowel diseases requiring treatment, gastric ulcer, duodenal ulcer or specific inflammations, such as Crohn's disease, or with a propensity for gastrointestinal bleeding in the upper tract, such as esophageal or gastric varices, or acquired intestinal telangiectasia;
☉ People with severe cardiopulmonary or organic disorders;
☉ Individuals with congenital or acquired anomalies of the gastrointestinal tract, such as atresias or stenoses; with a large hiatal hernia;
☉ Chemical dependents in general;
☉ Patients with any type of infection in the body;
☉ Patients with HIV;
☉ Patients taking medication that may cause any gastric irritation or complication;
☉ Patients with reflux esophagitis;
☉ Patients with esophageal stenosis or diverticulum;
☉ Patients with potentially hemorrhagic lesions, such as varices;
☉ Patients using anti-inflammatory drugs, anticoagulants, alcohol, or other drugs;
☉ Patients who have already developed serotonin syndrome and are currently taking any known drug that affects serotonin levels in the body, such as selective serotonin reuptake inhibitors, selective serotonin and adrenaline reuptake inhibitors, monoamine oxidase inhibitors, among others.

‍